KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacific Biosciences Of California (PACB) Total Liabilities (2016 - 2025)

Pacific Biosciences Of California has reported Total Liabilities over the past 16 years, most recently at $778.7 million for Q4 2025.

  • Quarterly results put Total Liabilities at $778.7 million for Q4 2025, up 3.3% from a year ago — trailing twelve months through Dec 2025 was $778.7 million (up 3.3% YoY), and the annual figure for FY2025 was $778.7 million, up 3.3%.
  • Total Liabilities for Q4 2025 was $778.7 million at Pacific Biosciences Of California, up from $767.1 million in the prior quarter.
  • Over the last five years, Total Liabilities for PACB hit a ceiling of $1.2 billion in Q4 2021 and a floor of $753.9 million in Q4 2024.
  • Median Total Liabilities over the past 5 years was $1.0 billion (2024), compared with a mean of $1.0 billion.
  • Biggest five-year swings in Total Liabilities: skyrocketed 1449.24% in 2021 and later dropped 27.84% in 2024.
  • Pacific Biosciences Of California's Total Liabilities stood at $1.2 billion in 2021, then fell by 0.97% to $1.2 billion in 2022, then fell by 13.24% to $1.0 billion in 2023, then dropped by 27.84% to $753.9 million in 2024, then rose by 3.3% to $778.7 million in 2025.
  • The last three reported values for Total Liabilities were $778.7 million (Q4 2025), $767.1 million (Q3 2025), and $764.0 million (Q2 2025) per Business Quant data.